Skip to content
PeptidesEncyclopedia
Informational, not medical advice

This is an approved / prescription medicine. Do not use without a prescription and medical supervision.

EMA-approvedaka Vibativ

Telavancin — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Telavancin (also known as Vibativ) is a peptide catalogued under Cyclic & Antimicrobial (Lipoglycopeptide). It is described as: Cell wall + membrane. Documented context: HABP/VABP; ABSSSI. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Telavancin?

Telavancin (brand name Vibativ) is a semisynthetic lipoglycopeptide antibiotic derived from vancomycin, FDA-approved in 2009 for complicated skin and skin-structure infections (later aligned to ABSSSI) and, since 2013, for hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible Staphylococcus aureus when alternative treatments are not suitable.

It carries an FDA boxed warning for nephrotoxicity (including increased mortality in patients with pre-existing moderate-to-severe renal impairment treated for HABP/VABP) and for fetal risk in pregnancy.

Evidence level is high, resting on paired pivotal phase 3 RCTs for each indication (ATLAS for skin infections; ATTAIN for nosocomial pneumonia).

How does Telavancin work?

Telavancin has a dual mechanism: it inhibits cell-wall peptidoglycan synthesis by binding D-Ala-D-Ala precursors, and its lipophilic side chain disrupts the bacterial membrane potential and permeability.

This produces rapid, concentration-dependent bactericidal activity against Gram-positive pathogens including MRSA.

What does the research say about Telavancin?

  • Telavancin was non-inferior to vancomycin for complicated skin and skin-structure infections in the pooled phase 3 ATLAS trials. [1]
  • In the phase 3 ATTAIN trials, telavancin was non-inferior to vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens. [2]
  • A pre-specified ATTAIN analysis found cure rates favored telavancin in patients without severe renal impairment, highlighting the renal-function-dependent benefit-risk balance. [3]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

  • [1] Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms — Stryjewski ME et al., Clinical Infectious Diseases 2008. (Phase 3 RCT (ATLAS))
  • [2] Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens — Rubinstein E et al., Clinical Infectious Diseases 2011. (Phase 3 RCT (ATTAIN))
  • [3] Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure — Torres A et al., Journal of Antimicrobial Chemotherapy 2014. (Pre-specified subgroup analysis)
  • [4] Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance — Pushkin R et al., Antimicrobial Agents and Chemotherapy 2015. (Post hoc analysis)
  • [5] Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides — Al Jalali V et al., Clinical Pharmacokinetics 2018. (Pharmacokinetic review)
  • [6] Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens — Das B et al., Therapeutic Advances in Infectious Disease 2017. (Narrative review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In the pivotal trials and labeling, telavancin is given as an intravenous infusion of 10 mg/kg once every 24 hours, with dose adjustment required for reduced creatinine clearance.

This is descriptive context for the approved indications only and is not medical advice or a dosing recommendation.

Side effects & safety profile

Telavancin carries an FDA boxed warning for nephrotoxicity, including higher mortality than vancomycin among HABP/VABP patients with pre-existing moderate-to-severe renal impairment, plus new-onset or worsening renal impairment; renal function should be monitored.

The boxed warning also flags fetal risk: telavancin caused adverse developmental outcomes in animals, so women of childbearing potential should have a serum pregnancy test before use and it should be avoided in pregnancy unless benefit outweighs risk.

Other cautions include taste disturbance, nausea, QTc prolongation, and interference with certain coagulation and urine-protein laboratory tests.

Stacking & combinations

Telavancin is used as monotherapy for its labeled indications and is not intended for combination outside clinician-directed hospital care.

Finding Telavancin vendors

Finding Telavancin vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Sign in to review

Frequently asked questions

For complicated/acute bacterial skin and skin-structure infections and, since 2013, for hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible S. aureus when other treatments are unsuitable.

References

  1. [1] Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms — Stryjewski ME et al., Clinical Infectious Diseases 2008. PMID: 18444791. View sourceStudy: Phase 3 RCT (ATLAS)Telavancin was non-inferior to vancomycin for complicated skin infections.
  2. [2] Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens — Rubinstein E et al., Clinical Infectious Diseases 2011. PMID: 21148517. View sourceStudy: Phase 3 RCT (ATTAIN)Telavancin was non-inferior to vancomycin for Gram-positive hospital-acquired pneumonia.
  3. [3] Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure — Torres A et al., Journal of Antimicrobial Chemotherapy 2014. PMID: 24398339. View sourceStudy: Pre-specified subgroup analysisCure rates favored telavancin once patients with severe renal impairment were excluded.
  4. [4] Telavancin for Acute Bacterial Skin and Skin Structure Infections, a Post Hoc Analysis of the Phase 3 ATLAS Trials in Light of the 2013 FDA Guidance — Pushkin R et al., Antimicrobial Agents and Chemotherapy 2015. PMID: 26248356. View sourceStudy: Post hoc analysisReanalyzed ATLAS under modern ABSSSI endpoints, supporting efficacy.
  5. [5] Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides — Al Jalali V et al., Clinical Pharmacokinetics 2018. PMID: 29332251. View sourceStudy: Pharmacokinetic reviewCharacterizes telavancin PK/PD relative to other glycopeptides.
  6. [6] Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens — Das B et al., Therapeutic Advances in Infectious Disease 2017. PMID: 28634536. View sourceStudy: Narrative reviewReviews telavancin's dual mechanism and role against resistant Gram-positives.
This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.